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Book Reviews
BIOMEDICAL POLITICS. (Kathi E. Hanna, ed., National Academy
Press 1991) [352 pp.] Preface and acknowledgements, Carl W. Gottschalk, Chair,
Institute of Medicine Committee to Study Biomedical Decision Making. Appendices,
biographical notes on authors and commentators, index, notes, references. LC 91-
18394, ISBN 0-309-04486-3. [Cloth $29.95. Export $36.00. 2101 Constitution
Ave., NW, Washington DC 20418.]
Six studies of cases chosen by Institute of Medicine Committee to
Study Biomedical Decision Making to illustrate the complexity and
evolution of decision making related to the diffusion and adoption of
advances in biomedicine constitute the heart of this book. The cases
chosen were: (1) the unproven AIDS therapy dideoxyinosine; (2) RU-
486, a drug furnishing an alternative to early abortions; (3) the Human
Genome Project; (4) an entitlement program for victims of end-stage
renal disease; (5) human fetal tissue transplantation; and (6) the
restrictions on recombinant DNA research adopted at the Asilomar
Conference. As explained by respective authors, their research materials
varied widely, being based upon, e.g., interviews with involved
individuals, planning documents, scientific and lay literature, meeting
transcripts, and records from congressional debate.
The committee, itself, is also represented in an introduction, twelve
commentaries written by committee members (two follow each case
study), and a final chapter summarizing committee conclusions and
suggestions for further research. Moreover, committee member Stanley
Joel Reiser prepared a paper discussing the historical roles of the public
and experts in biomedical policy controversies; this appears as an
appendix.
Taken together, the studies in this book provide a good sample of
the range of decision-making processes that have been used to resolve
complex scientific and medical issues once they have been subjected to
public scrutiny. The book is interesting and well written - in language
easily understandable by a wide audience. Also, the commentaries were
designed to keep the overall presentation of each topic as objective as
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BIOMEDICAL POLITICS demonstrates that important biomedical
decisions are at least as much influenced by chance, fate and politics as
they are by the merits. This book is highly recommended to anyone
interested in how public controversies over highly technical subject
matter may be resolved - whether or not the subject matter be, in any
sense, biomedical.
Each topic could easily be the subject of a book as long as this one,
but such a span of pages would defeat its purpose. Nevertheless, it is
recommended to anyone seeking an even-handed summary of any of the
addressed controversies, and those seeking further information will find
the reference lists helpful.
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